A Multicenter, Prospective Cohort Study of Preserved Ratio Impaired Spirometry(PRISm) in a Population - Trial NCT06340295
Access comprehensive clinical trial information for NCT06340295 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking University First Hospital and is currently Recruiting. The study focuses on COPD. Target enrollment is 2000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Peking University First Hospital
Timeline & Enrollment
N/A
Sep 01, 2023
May 31, 2026
Primary Outcome
The number and proportion of newly diagnosed COPD
Summary
Chronic obstructive pulmonary disease (COPD) is the most common chronic tract disease and the
 third leading cause of death worldwide. The treatment effect of COPD is poor, and the disease
 is progressive, resulting in a serious disease burden. The key reason is that early
 recognition is difficult and the early pathophysiological mechanism is unclear, which leads
 to the difficulty of early intervention.PRISm is likely to be the precursor stage of COPD,
 which may provide an important research object for the study of pathophysiological
 characteristics, inflammation and immunomodulatory mechanisms of early COPD, and may also
 become a new entry point for early intervention of COPD. This study attempts to establish a
 PRISm prospective cohort๏ผand collects blood, EBC and urine for analysis of inflammatory
 factors, metabolomics, proteomics and microbiome, and performs chest HRCT to obtain imaging
 indicators, and conducts 3-year dynamic follow-up observation to study the evolution
 characteristics of pulmonary function and the incidence of COPD in the PRISm cohort. To
 compare the differences in imaging, inflammatory factors, metabolomics, proteomics and
 microbiome among the three PRISm groups, and establish a risk prediction model for
 progression to COPD through PRISm. It lays a foundation for understanding the characteristics
 of COPD at an earlier stage and exploring new early warning indicators.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06340295
Non-Device Trial

